+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Biologics Market by Product Type, Cancer Type, End User, Distribution Channel - Global Forecast to 2030- Product Image
Cancer Biologics Market by Product Type, Cancer Type, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Cancer Biologics Market by Product Type, Cancer Type, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011651
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Biologics Market grew from USD 102.05 billion in 2024 to USD 108.88 billion in 2025. It is expected to continue growing at a CAGR of 6.44%, reaching USD 148.45 billion by 2030.

Pioneering the Future of Cancer Biologics with Strategic Insights

The cancer biologics market stands at an inflection point where scientific breakthroughs and strategic imperatives converge to redefine therapeutic possibilities. Recent advancements in molecular biology, immuno-oncology, and bioprocessing technologies have accelerated the development of next-generation biologics, offering unprecedented potential for durable responses and personalized treatment protocols. In parallel, evolving regulatory frameworks and collaborative ecosystems are fostering an environment in which innovation can flourish while maintaining rigorous safety and efficacy standards.

Understanding these dynamics is crucial for decision-makers aiming to navigate a landscape marked by rapid change and intense competition. This introduction outlines the foundational drivers shaping the cancer biologics sector and sets the stage for a detailed exploration of transformative trends, policy impacts, segmentation insights, and regional developments. With this context in place, stakeholders can better anticipate emerging opportunities, align resources effectively, and position their organizations to capitalize on the promise of biologic therapies in oncology.

Catalyzing Innovation through Shifting Therapeutic Paradigms

Emerging modalities such as cell and gene therapies are reshaping therapeutic paradigms, shifting the focus from symptom management to curative intent. Advances in chimeric antigen receptor T cell engineering and novel viral vector platforms have demonstrated profound clinical efficacy, prompting a recalibration of research priorities and investment streams. Meanwhile, the integration of real-world data and artificial intelligence into drug discovery pipelines is enhancing target identification and accelerating clinical trial design.

Concurrently, patient-centric care models are gaining traction, driven by increased advocacy and demand for personalized treatment regimens. Regulatory agencies are responding with adaptive approval pathways that balance expedited access against robust post-market surveillance. This evolving landscape underscores a transformative era where collaboration between biotech innovators, academic institutions, payers, and regulators will be essential to sustain momentum and deliver on the promise of next-generation biologics.

Navigating the Impact of 2025 United States Tariffs on Oncology Biologics

The impending implementation of United States tariffs in 2025 is poised to introduce a complex layer of economic considerations for manufacturers of cancer biologics. Tariff adjustments on critical raw materials, such as single-use bioprocessing components and active pharmaceutical ingredients, may lead to cost escalations that reverberate throughout supply chains. These additional duties could incentivize onshoring of manufacturing operations or the renegotiation of supplier contracts to maintain margin integrity.

Moreover, the duty landscape will influence strategic decisions regarding global distribution networks, potentially prompting organizations to reassess warehousing locations, inventory buffers, and logistics partnerships. Navigating these shifts will require a granular understanding of tariff classifications and harmonized system codes specific to biologic products. Companies that anticipate and adapt to these changes proactively will be better positioned to mitigate financial risk and preserve uninterrupted patient access to vital therapies.

Decoding Market Segmentation to Uncover Growth Opportunities

A nuanced examination of market segmentation reveals distinctive growth trajectories and strategic imperatives across product portfolios and end markets. In the realm of therapeutic modalities, recombinant proteins and monoclonal antibodies dominate current revenues, yet cell and gene therapies are gaining momentum with breakthrough designations. Within monoclonal antibodies, anti-PD-1/PD-L1 agents such as Atezolizumab, Nivolumab, and Pembrolizumab have become frontline options in multiple indications, while anti-CD20 therapies like Obinutuzumab and Rituximab continue to expand their utility in hematological malignancies. Agents targeting HER2, including Pertuzumab and Trastuzumab, remain integral to breast cancer regimens, and anti-VEGF treatments exemplified by Bevacizumab sustain significant demand across colorectal and lung cancers.

Turning to cancer types, breast and lung cancers command substantial research funding and clinical trial activity, reflecting high incidence and unmet medical need. Hematological malignancies benefit from an established biologics framework, while melanoma therapies demonstrate accelerating adoption of checkpoint inhibitors. Colorectal and prostate cancers, though historically served by small molecules and cytotoxics, are increasingly explored through immuno-oncology combinations. Analysis of end user channels underscores the pivotal role of oncology centers in pioneering novel regimens, with homecare settings emerging as a critical extension of patient-centric delivery models. Ambulatory surgery centers and hospital clinics act as essential conduits, ensuring seamless administration of infusion-based therapies. Distribution channels further influence market access dynamics, with specialty distributors and hospital pharmacies leading in handling complex biologics, while online and retail pharmacies facilitate broader patient reach for subcutaneous and self-administered products.

Unveiling Regional Dynamics Shaping Global Cancer Biologics

Regional dynamics in cancer biologics are shaped by diverse regulatory frameworks, healthcare infrastructure maturity, and payer ecosystems. In the Americas, robust R&D investments and a streamlined approval process support rapid commercialization, though pricing negotiations with private and public payers remain a critical hurdle. North America’s integrated healthcare systems facilitate the implementation of value-based contracts and real-world evidence studies, reinforcing leadership in biologics adoption.

In Europe, Middle East & Africa, market access is influenced by centralized regulatory oversight and heterogeneous reimbursement landscapes. The European Union continues to harmonize approval pathways through adaptive frameworks, while reimbursement decisions vary by member state, driving manufacturers to develop differentiated access strategies. Emerging markets across the Middle East and Africa are witnessing incremental uptake of advanced therapies, underpinned by investments in healthcare infrastructure and public-private partnerships.

The Asia-Pacific region exhibits dynamic growth, fueled by expanding biosimilar launches, government-led innovation initiatives, and growing demand for personalized oncology. Countries such as China, Japan, and South Korea are bolstering domestic manufacturing capabilities and forging global collaborations. At the same time, market liberalization and progressive pricing reforms are enhancing affordability and fostering broader patient access across the region.

Profiling Key Industry Leaders Driving Biologic Breakthroughs

The competitive landscape features established biopharmaceutical leaders alongside agile biotechnology firms driving specialized innovations. Global powerhouses leverage extensive pipelines and manufacturing scale to sustain dominance in core monoclonal antibody classes while pursuing strategic acquisitions to enhance cell and gene therapy capabilities. In parallel, emerging biotech companies are securing partnership agreements to co-develop next-generation modalities, often focusing on niche indications or novel delivery platforms.

Strategic alliances between large pharma and academic entities are accelerating translational research, particularly in areas such as neoantigen vaccines and combination immunotherapies. Contract development and manufacturing organizations are expanding their service offerings to accommodate the complexity of autologous and allogeneic cell therapies, positioning themselves as critical enablers of commercial-scale production. Investors are closely monitoring clinical milestones and regulatory advancements, shifting capital toward programs that demonstrate differentiated mechanisms of action and favorable safety profiles. Companies that combine robust clinical data with scalable manufacturing strategies will be best equipped to capture leadership positions in this rapidly evolving sector.

Implementing Targeted Strategies for Competitive Advantage

Industry leaders should prioritize the optimization of global supply chains by implementing digital tracking solutions and diversifying supplier portfolios to guard against tariff-related disruptions. Investing in flexible manufacturing platforms, including modular facilities and single-use technologies, will allow for rapid scale-up of both established and novel biologics. Aligning research efforts with payer requirements through early health technology assessments can expedite reimbursement discussions and market access.

Moreover, forging collaborative ecosystems with academic institutions and technology partners will enhance innovation velocity, particularly in complex modalities like gene editing and personalized vaccines. Companies should also strengthen patient engagement strategies by leveraging digital health tools to monitor outcomes and support adherence, thereby generating real-world evidence that reinforces product value. Finally, developing region-specific market entry plans will ensure tailored approaches to regulatory submissions, pricing negotiations, and distribution partnerships, setting a foundation for sustainable growth across diverse geographies.

Applying Rigorous Methodology to Deliver Actionable Intelligence

This analysis integrates primary research, secondary data sources, and expert interviews to ensure comprehensive coverage of the cancer biologics landscape. Primary insights were garnered through structured discussions with industry executives, clinical investigators, and payer representatives, yielding firsthand perspectives on market drivers and barriers. Secondary research encompassed corporate filings, regulatory agency databases, conference proceedings, and peer-reviewed literature to validate trends and benchmark competitive activity.

Quantitative data were synthesized to map product portfolios against therapeutic indications, manufacturing capacities, and distribution networks. Qualitative assessments were conducted to evaluate strategic initiatives, partnership models, and policy impacts. Triangulation of findings across multiple data sets enhanced the rigor of sector forecasts and identified areas requiring further validation. Throughout the process, quality controls were applied via cross-functional reviews and adherence to industry-standard research protocols, ensuring reliability and actionable relevance.

Synthesizing Insights to Chart the Path Forward in Cancer Biologics

The confluence of technological advancements, evolving regulatory landscapes, and shifting market dynamics underscores a transformative era for cancer biologics. Stakeholders equipped with a deep understanding of segmentation nuances, regional variations, and competitive positioning will be poised to capitalize on emerging opportunities. By anticipating tariff impacts and aligning development pipelines with payer expectations, organizations can mitigate risks and accelerate time to market.

Strategic collaborations and patient-centric innovations will remain pivotal as the sector advances toward more personalized and curative therapies. Rigorous research methodologies and real-world evidence generation will support sustainable value propositions and inform adaptive reimbursement models. The insights presented herein offer a foundation for informed decision-making, enabling industry participants to navigate complexity, drive innovation, and improve patient outcomes in the evolving oncology landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Cancer Vaccines
    • Cell Therapy
    • Gene Therapy
    • Monoclonal Antibodies
      • Anti-CD20
        • Obinutuzumab
        • Rituximab
      • Anti-HER2
        • Pertuzumab
        • Trastuzumab
      • Anti-PD-1/PD-L1
        • Atezolizumab
        • Nivolumab
        • Pembrolizumab
      • Anti-VEGF
        • Bevacizumab
    • Recombinant Proteins
  • Cancer Type
    • Breast Cancer
    • Colorectal Cancer
    • Hematological Malignancies
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
  • End User
    • Ambulatory Surgery Centers
    • Homecare Settings
    • Hospitals & Clinics
    • Oncology Centers
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • Specialty Distributors
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Amgen Inc
  • Pfizer Inc
  • AstraZeneca PLC
  • Novartis AG
  • Gilead Sciences, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Biologics Market, by Product Type
8.1. Introduction
8.2. Cancer Vaccines
8.3. Cell Therapy
8.4. Gene Therapy
8.5. Monoclonal Antibodies
8.5.1. Anti-CD20
8.5.1.1. Obinutuzumab
8.5.1.2. Rituximab
8.5.2. Anti-HER2
8.5.2.1. Pertuzumab
8.5.2.2. Trastuzumab
8.5.3. Anti-PD-1/PD-L1
8.5.3.1. Atezolizumab
8.5.3.2. Nivolumab
8.5.3.3. Pembrolizumab
8.5.4. Anti-VEGF
8.5.4.1. Bevacizumab
8.6. Recombinant Proteins
9. Cancer Biologics Market, by Cancer Type
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Hematological Malignancies
9.5. Lung Cancer
9.6. Melanoma
9.7. Prostate Cancer
10. Cancer Biologics Market, by End User
10.1. Introduction
10.2. Ambulatory Surgery Centers
10.3. Homecare Settings
10.4. Hospitals & Clinics
10.5. Oncology Centers
11. Cancer Biologics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
11.5. Specialty Distributors
12. Americas Cancer Biologics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Cancer Biologics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Cancer Biologics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. F. Hoffmann-La Roche Ltd
15.3.2. AbbVie Inc
15.3.3. Bristol-Myers Squibb Company
15.3.4. Merck & Co., Inc.
15.3.5. Johnson & Johnson
15.3.6. Amgen Inc
15.3.7. Pfizer Inc
15.3.8. AstraZeneca PLC
15.3.9. Novartis AG
15.3.10. Gilead Sciences, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CANCER BIOLOGICS MARKET MULTI-CURRENCY
FIGURE 2. CANCER BIOLOGICS MARKET MULTI-LANGUAGE
FIGURE 3. CANCER BIOLOGICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CANCER BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CANCER BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CANCER BIOLOGICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY SPECIALTY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 68. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 69. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 70. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 71. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 72. CANADA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 73. CANADA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. CANADA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 78. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 79. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 80. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 81. MEXICO CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 82. MEXICO CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. MEXICO CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. GERMANY CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. GERMANY CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 123. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 124. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 126. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 127. GERMANY CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 128. GERMANY CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. GERMANY CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. FRANCE CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. FRANCE CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 132. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 133. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 134. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 135. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 136. FRANCE CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 137. FRANCE CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. FRANCE CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. ITALY CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. ITALY CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 150. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 151. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 152. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 153. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 154. ITALY CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 155. ITALY CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. ITALY CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SPAIN CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SPAIN CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 159. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 160. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 161. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 162. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 163. SPAIN CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 164. SPAIN CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SPAIN CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. DENMARK CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 194. DENMARK CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 195. DENMARK CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 196. DENMARK CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 197. DENMARK CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 198. DENMARK CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 199. DENMARK CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 200. DENMARK CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. DENMARK CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 209. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. QATAR CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. QATAR CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 213. QATAR CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 214. QATAR CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 215. QATAR CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 216. QATAR CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 217. QATAR CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 218. QATAR CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. QATAR CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. FINLAND CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. FINLAND CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 222. FINLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 223. FINLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 224. FINLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 225. FINLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 226. FINLAND CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 227. FINLAND CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. FINLAND CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. EGYPT CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. EGYPT CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 249. EGYPT CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 250. EGYPT CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 251. EGYPT CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 252. EGYPT CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 253. EGYPT CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 254. EGYPT CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. EGYPT CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. TURKEY CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 257. TURKEY CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 258. TURKEY CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 259. TURKEY CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 260. TURKEY CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 261. TURKEY CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 262. TURKEY CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 263. TURKEY CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. TURKEY CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. NORWAY CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 276. NORWAY CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 277. NORWAY CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 278. NORWAY CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 279. NORWAY CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 280. NORWAY CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 281. NORWAY CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. NORWAY CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. POLAND CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. POLAND CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 285. POLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 286. POLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 287. POLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 288. POLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 289. POLAND CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 290. POLAND CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. POLAND CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 311. CHINA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 312. CHINA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 313. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 314. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 315. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 316. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 317. CHINA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 318. CHINA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. CHINA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 320. INDIA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 321. INDIA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 322. INDIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 323. INDIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 324. INDIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 325. INDIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 326. INDIA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 327. INDIA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. INDIA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. JAPAN CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 330. JAPAN CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 331. JAPAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 332. JAPAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 333. JAPAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 334. JAPAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 335. JAPAN CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 336. JAPAN CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 337. JAPAN CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 340. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 341. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 342. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 343. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 344. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 345. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 346. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 347. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 348. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 349. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2030 (USD MILLION)
TABLE 350. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2030 (USD MILLION)
TABLE 351. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2030 (USD MILLION)
TABLE 352. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 353. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 354. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 355. SOUTH KOREA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cancer Biologics market report include:
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Amgen Inc
  • Pfizer Inc
  • AstraZeneca PLC
  • Novartis AG
  • Gilead Sciences, Inc.

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 108.88 Billion
Forecasted Market Value ( USD ) by 2030 $ 148.45 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Biologics Market by Product Type, Therapeutic Area, Technology, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Biologics Market by Product Type, Therapeutic Area, Technology, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Biologics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Biologics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 170 Pages
  • Global
From
Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 180 Pages
  • Global
From

About the Cancer Biologics Market

The Cancer Biologics market is a subset of the larger Biotechnology industry. It focuses on the development and commercialization of biologic drugs for the treatment of cancer. These drugs are typically derived from living organisms, such as proteins, antibodies, and other molecules, and are used to target and treat cancer cells. They are often used in combination with other treatments, such as chemotherapy and radiation therapy, to improve outcomes. Cancer biologics are typically developed through a combination of laboratory research, clinical trials, and regulatory approval. Companies in this market are typically involved in the research, development, manufacturing, and marketing of these drugs. Notable companies in the Cancer Biologics market include Amgen, Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.